A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Viracta Therapeutics, Inc. (“Viracta” or the “Company”) is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. The association of viruses and cancer has been well characterized, and Viracta’s lead program is focused on cancers associated with the Epstein-Barr virus (“EBV”). EBV has been recognized as a Group 1 human carcinogen by the World Health Organization (“WHO”). Despite the association of EBV with cancer, there are currently no approved therapies in the United States specifically for EBV-associated cancers and attempts to develop vaccines have not proven successful. EBV enters periods of latency during which most viral genes are epigenetically suppressed. Likewise, the latently infected cell can evade the body’s immune surveillance mechanisms. In some stages of latency, viral proteins are not expressed on the cell surface, making it difficult to develop effective immunotherapies.
| Metric | TTM | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -43M | -22M | -23M | -27M | -35M | -38M |
| EPS | $-1.10 | $-1.53 | $-2.68 | $-0.75 | $-1.45 | $-2.42 |
| Free Cash Flow | 0 | -21M | -22M | -24M | -36M | -37M |
| ROIC | -169.9% | -88.4% | -84.7% | -508.7% | -126.2% | -66.6% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.17 | 0.35 | 2.84 | 0.59 | 0.53 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -47M | -22M | -23M | -26M | -34M | -36M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | 0.0% | -91.0% | -84.7% | -666.5% | -164.6% | -180.9% |
| Shares Outstanding | 40M | 14M | 9M | 35M | 24M | 16M |
Viracta Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Viracta Therapeutics, Inc. (VIRX) has a 5-year average return on invested capital (ROIC) of -91.5%. This is below average and may indicate limited pricing power.
Viracta Therapeutics, Inc. (VIRX) has a market capitalization of $389K. It is classified as a small-cap stock.
Viracta Therapeutics, Inc. (VIRX) does not currently pay a regular dividend.
Viracta Therapeutics, Inc. (VIRX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Viracta Therapeutics, Inc. (VIRX) generated $-21 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Viracta Therapeutics, Inc. (VIRX) has a debt-to-equity ratio of 0.17. This indicates a conservatively financed balance sheet.
Viracta Therapeutics, Inc. (VIRX) reported earnings per share (EPS) of $-1.53 in its most recent fiscal year.
Viracta Therapeutics, Inc. (VIRX) has a return on equity (ROE) of -91.0%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 11 years of financial data for Viracta Therapeutics, Inc. (VIRX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Viracta Therapeutics, Inc. (VIRX) has a book value per share of $1.41, based on its most recent annual SEC filing.